{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:19:53Z","timestamp":1770916793135,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015383","name":"Foundation for Liver and Gastrointestinal Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Serum hepatitis B surface antigen (HBsAg) levels correlate with the duration of chronic hepatitis B virus (HBV) infection and may predict the extent of hepatic fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from the SONIC-B database, which contains data from 8 global randomized trials and 2 large hepatology centers. Relationship between HBsAg levels and presence of significant fibrosis (Ishak 3\u20134) or cirrhosis (Ishak 5\u20136) were explored, and clinically relevant cutoffs were identified to rule out cirrhosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The dataset included 2779 patients: 1866 hepatitis B e antigen (HBeAg)-positive; 322 with cirrhosis. Among HBeAg-positive patients, lower HBsAg levels were associated with higher rates of significant fibrosis (odds ratio [OR], 0.419; P &amp;lt; .001) and cirrhosis (OR, 0.435; P &amp;lt; .001). No relationship was observed among HBeAg-negative patients. Among HBeAg-positive patients, genotype-specific HBsAg cutoffs had excellent negative predictive values (&amp;gt;97%) and low misclassification rates (\u22647.1%) and may therefore have utility in ruling out cirrhosis. Diagnostic performance of the HBsAg cutoffs was comparable among patients in whom cirrhosis could not be ruled out with fibrosis 4 (FIB-4).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Hepatitis B virus genotype-specific HBsAg cutoffs may have utility in ruling out presence of cirrhosis in HBeAg-positive patients with genotypes B, C, and D and can be an adjunct to FIB-4 to reduce the need for further testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa192","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:05:42Z","timestamp":1587236742000},"page":"1967-1973","source":"Crossref","is-referenced-by-count":17,"title":["Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study"],"prefix":"10.1093","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-563X","authenticated-orcid":false,"given":"Milan J","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC , Rotterdam, The Netherlands"},{"name":"University Medical Center , Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E","family":"Hansen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, University Health Network , Toronto, Canada"},{"name":"IHPME, University of Toronto , Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-1481","authenticated-orcid":false,"given":"Willem P","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC , Rotterdam, The Netherlands"},{"name":"University Medical Center , Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry L-Y","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics and Institute of Digestive Disease, the Chinese University of Hong Kong , Hong Kong Special Administrative Region, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[{"name":"NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University , Hat Yai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Dong","family":"Jia","sequence":"additional","affiliation":[{"name":"Liver Research Center, Beijing Friendship Hospital, Capital Medical University , Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, Johann Wolfgang Goethe University Medical Center , Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[{"name":"Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine , Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"de Knegt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC , Rotterdam, The Netherlands"},{"name":"University Medical Center , Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Wat","sequence":"additional","affiliation":[{"name":"Roche Product Ltd. , Welwyn Garden City, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedran","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Roche Product Ltd. , Welwyn Garden City, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron and CIBEHED del Instituto Carlos III , Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"de Man","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC , Rotterdam, The Netherlands"},{"name":"University Medical Center , Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L A","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC , Rotterdam, The Netherlands"},{"name":"University Medical Center , Rotterdam, The Netherlands"},{"name":"Toronto Centre for Liver Disease, University Health Network , Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SONIC-B Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"2022060114582726300_CIT0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"2022060114582726300_CIT0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2022060114582726300_CIT0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado","year":"2015","journal-title":"J Hepatol"},{"key":"2022060114582726300_CIT0004","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2468-1253(19)30087-1","article-title":"Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study","volume":"4","author":"Sonneveld","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022060114582726300_CIT0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijid.2014.08.005","article-title":"Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B","volume":"29","author":"Harkisoen","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2022060114582726300_CIT0006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2013.01.028","article-title":"Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-na\u00efve, e antigen-positive patients","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Hepatol"},{"key":"2022060114582726300_CIT0007","doi-asserted-by":"crossref","first-page":"86463","DOI":"10.18632\/oncotarget.21210","article-title":"Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"2022060114582726300_CIT0008","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2022060114582726300_CIT0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"2022060114582726300_CIT0010","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","article-title":"A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B","volume":"105","author":"Rijckborst","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2022060114582726300_CIT0011","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/jvh.12468","article-title":"Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients","volume":"23","author":"Brouwer","year":"2016","journal-title":"J Viral Hepat"},{"key":"2022060114582726300_CIT0012","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060114582726300_CIT0013","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"2022060114582726300_CIT0014","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"2022060114582726300_CIT0015","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060114582726300_CIT0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir Ther"},{"key":"2022060114582726300_CIT0017","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","article-title":"Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?","volume":"61","author":"Janssen","year":"2012","journal-title":"Gut"},{"key":"2022060114582726300_CIT0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2010.10.027","article-title":"Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B","volume":"55","author":"Manesis","year":"2011","journal-title":"J Hepatol"},{"key":"2022060114582726300_CIT0019","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"key":"2022060114582726300_CIT0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.25636","article-title":"Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B","volume":"56","author":"Sonneveld","year":"2012","journal-title":"Hepatology"},{"key":"2022060114582726300_CIT0021","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.12787","article-title":"Precore\/core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B","volume":"35","author":"Lapalus","year":"2015","journal-title":"Liver Int"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa192\/33222739\/jiaa192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/11\/1967\/43918286\/jiaa192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/11\/1967\/43918286\/jiaa192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T14:59:27Z","timestamp":1654095567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/11\/1967\/5823493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,4,21]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa192","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2020,4,21]]}}}